BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 29359475)

  • 1. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
    Dale GH; Svendsen KB; Gjelstrup MC; Christensen T; Houen G; Nielsen E; Bek T; Petersen T
    Acta Neurol Scand; 2018 Jun; 137(6):582-588. PubMed ID: 29359475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
    Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
    Rajput HM; Hassan M; Badshah M
    Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries.
    Viktoria P; Trones KDP; Magyari M; Koch-Henriksen N; Iljicsov A; Rajda C; Nielsen HH; Lovas G; Rozsa C; Kristiansen BH; Stenager E; Frederiksen JL; Komoly S; Sellebjerg F; Petersen T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102879. PubMed ID: 33714126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients.
    He M; Wu L; Huang D; Yu S
    Mult Scler Relat Disord; 2020 Nov; 46():102459. PubMed ID: 32853894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Hamid SH; Elsone L; Mutch K; Solomon T; Jacob A
    Mult Scler; 2017 Feb; 23(2):228-233. PubMed ID: 27553618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
    Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria.
    Rattanathamsakul N; Kaveeta C; Siritho S; Thakolwiboon S; Prayoonwiwat N
    Mult Scler Relat Disord; 2020 Aug; 43():102218. PubMed ID: 32474289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Hyun JW; Jeong IH; Joung A; Kim SH; Kim HJ
    Neurology; 2016 May; 86(19):1772-9. PubMed ID: 27164713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients.
    Kishk NA; Abokrysha NT; Rashed L; Ahmed N
    J Clin Neurosci; 2015 Apr; 22(4):670-5. PubMed ID: 25677878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of inflammation in neuromyelitis optica spectrum disorders.
    Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
    Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis.
    Bagherieh S; Afshari-Safavi A; Vaheb S; Kiani M; Ghaffary EM; Barzegar M; Shaygannejad V; Zabeti A; Mirmosayyeb O
    Neurol Sci; 2023 Jun; 44(6):1905-1915. PubMed ID: 36745300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.